Management continues to execute well, and to adhere pretty closely to its timelines. The CT-006 registrational trial is now underway, with topline in 2027. A further partnership continues to be targeted for 2026, and we should see low-grade glioma data as well, so there is some news-flow in the very short term ahead of the big one in 2027. We reiterate our SEK 101-117 fair value range.
LÄS MER
